Carregant...
Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning
The increasing appreciation of oncogenic driver alterations in non-small cell lung cancer (NSCLC) has resulted in a rapid expansion of therapeutic compounds. Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) alterations are the prototypical examples and have driven the par...
Guardat en:
| Publicat a: | Transl Lung Cancer Res |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AME Publishing Company
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4630509/ https://ncbi.nlm.nih.gov/pubmed/26629439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.07.03 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|